Article information
Full text is only available in PDF
Bibliografía
[1.]
Grupo de trabajo sobre GPC. Elaboración de Guías de Práctica Clínica en el Sistema Nacional de Salud. Manual Metodológico. Madrid: Plan Nacional para el SNS del MSC. Instituto Aragonés de Ciencias de la Salud-I+CS; 2007. Guías de Práctica Clínica en el SNS: I+CS N.° 2006/0I.
[2.]
GINA 2006. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention NHLBI/WHO Workshop Report. 2006. http://www.ginasthma.com.
[3.]
NAEPP-EP3 2007 Nacional Asthma Education and Prevention Program.
Expert Panel Report 3: Guidelines for the diagnosis and management of asthma.
National Institutes of Health, National Heart, Lung, and Blood Institute, (2007),
[4.]
BTS 2007. British Thoracic Society, Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. 2007. http://www.sign.ac.uk/guidelines. Thorax. 2008; 63(Suppl 4): iv1-121.
[5.]
G.H. Guyatt, A.D. Oxman, G.E. Vist, R. Kunz, Y. Falck-Ytter, P. Alonso-Coello, GRADE Working Group, et al.
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.
BMJ, 336 (2008), pp. 924-926
[6.]
ECRHHS.
The European Community Respiratory Health Survey II.
Eur Respir J, 20 (2002), pp. 1071-1079
[7.]
ISAAC.
ISAAC STEERING COMMITE. Variations in the prevalence of respiratory symptoms, self-reported asthma attacks, and use of asthma medication in the European Community Respiratory Health Survey (ECRHS).
Eur Respir, 9 (1996), pp. 687-695
[8.]
Grupo Español del Estudio Europeo en Asma.
Estudio europeo del asma Prevalencia de hiperreactividad bronquial y asma en jóvenes en 5 regiones de España. Grupo español del estudio europeo del asma.
Med Clin (Barc), 106 (1996), pp. 761-767
[9.]
J. Martínez Moratalla, E. Alma, J. Sunyer, J. Ramos, A. Pereira, F. Payo, et al.
Grupo Español de Estudio Europeo del Asma. Identificación y tratamiento de individuos con criterios epidemiologicos de asma en adultos jóvenes de cinco áreas espanolas.
Arch Bronconeumol, 35 (1999), pp. 223-228
[10.]
V. Sobradillo, M. Miravitlles, C.A. Jiménez, R. Gabriel, J.L. Viejo, J.F. Masa, et al.
Estudio IBERPOC en España: prevalencia de síntomas respiratorios habituales y de limitacion cronica al flujo aéreo.
Arch bronconeumol, 35 (1999), pp. 159-166
[11.]
I. Carvajal-Ureña, L. Garcia-Marcos, R. Busquets-Monge, M. Morales Sánchez-Varela, N. Garcia De Andoain, ISAAC, et al.
Variaciones geográficas de la prevalencia de síntomas de asma en los ninos y adolescentes españoles. International Study of Asthma and Allergies in Childhood (ISAAC) Fase III España.
Arch Bronconeumol, 41 (2005), pp. 659-666
[12.]
L. Cohn, J.A. Elías, G.L. Chupp.
Asthma mechanisms of disease persistence and progression.
Annu Rev Innunol, 22 (2004), pp. 789-815
[13.]
J. Douwes, P. Gibson, J. Pekkanen, N. Pearce.
Non eosinophilic asthma: importance and possible mechanisms.
Thorax, 57 (2002), pp. 643-648
[14.]
C.S. Murray, A. Woodcock, S.J. Langley, J. Morris, A. Custovic.
Secondary prevention of asthma by the use of Inhaled Fluticasone propionate in Wheezy Infants (IFWIN): double-blind, randomised, controlled study.
Lancet, 368 (2006), pp. 754-762
[15.]
S.J. Hirst, J.G. Martín, J.V. Bonacci, V. Chan, E.D. Fixman, Q.A. Hamid, et al.
Proliferative aspects of airway smooth muscle.
J Allergy Clin Immunol, 114 (2004), pp. S2-S17
[16.]
M. Hoshino, Y. Nakamura, Q. Hamid.
Gene expresion of vascular endothelial growth factor and its receptors and angiogenesis in bronchial asthma.
J Allergy Clin Immunol, 107 (2001), pp. 1034-1038
[17.]
C.E. Brightling, P. Bradding, F.A. Symon, S.T. Holgate, A.J. Wardlaw, I.D. Pavord.
Mastcell infiltration of airway smooth muscle in asthma.
N Engl J Med, 346 (2002), pp. 1699-1705
[18.]
G.J. Gleich.
Mechanisms of eosinophilassociated inflammation.
J Allergy Clin Immunol, 105 (2000), pp. 651-663
[19.]
J.V. Fahy, K.W. Kim, J. Liu, H.A. Boushey.
Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation.
J Allergy Clin Immunol, 95 (1995), pp. 843-852
[20.]
M. Peters-Golden.
The alveolar macrophage: the forgotten cell in asthma.
Am J Respir Cell Mol Biol, 31 (2004), pp. 3-7
[21.]
A.J. Polito, D. Proud.
Epithelia cells as regulators of airway inflammation.
J Allergy Clin Immunol, 102 (1998), pp. 714-718
[22.]
D.A. Groneberg, D. Quarcoo, N. Frossard, A. Fischer.
Neurogenic mechanisms in bronchial inflammatory diseases.
Allergy, 59 (2004), pp. 1139-1152
[23.]
C.S. Murray.
Can inhaled corticosteroids influence the natural history of asthma?.
Curr Opin Allergy Clin Immunol, 8 (2008), pp. 77-78
[24.]
S.T. Holgate, R. Polosa.
The mechanisms, diagnosis, and management of severe asthma in adults.
Lancet, 368 (2006), pp. 780-793
[26.]
J.W. Holloway, T.P. Keith, D.E. Davies, R. Powell, H.M. Haitchi, S.T. Holgate.
The discovery and role of ADAM 33, a new candidate gene for asthma.
Expert Rev Mol Med, 6 (2004), pp. 1-12
[27.]
V. Brusasco, E. Crimi, R. Pellegrino.
Airway hyperresponsiveness in asthma: not just a matter of airway inflammation.
Thorax, 53 (1998), pp. 992-998
[28.]
J.O. Warner, C.K. Naspitz.
Third International Pediatric Consensus statement on the management of childhood asthma. International Pediatric Asthma Consensus Group.
Pediatr Pulmonol, 25 (1998), pp. 1-17
[29.]
J.A. Castillo Laita, J. De Benito Fernández, A. Escribano Montaner, M. Fernández Benítez, S. García de la Rubia, J. Garde Garde, et al.
Consenso sobre tratamiento del asma en pediatría.
An Pediatr (Barc), 67 (2007), pp. 253-273
[30.]
F.D. Martínez, A.L. Wright, L.M. Taussig, C.J. Holberg, M. Halonen, W.J. Morgan.
Asthma and wheezing in the first six years of life. The Group Health Medical Associates.
N Engl J Med, 332 (1995), pp. 133-138
[31.]
J.A. Castro-Rodríguez, C.J. Holberg, A.L. Wright, F.D. Martínez.
A clinical index to define risk of asthma in young children with recurrent wheezing.
Am J Respir. Crit Care Med, 162 (2000), pp. 1403-1406
[32.]
T.W. Gilbert, W.J. Morgan, R.S. Zeiger.
Atopic characteristics of children with recurrent wheezing at high risk for the development of childhood asthma.
J Allergy Clin Immunol, 114 (2004), pp. 1282-1287
[33.]
BTS 2004.
British guideline on the management of asthma. A national clinic guideline.
Edinburg, (2004),
[34.]
W. Buke, M. Fesinmeyer, K. Reed, L. Hampson, C. Carlsten.
Family historyas a predictor of asthma risk.
Am J Prev Med, 24 (2003), pp. 160-169
[35.]
R. Pellegrino, G. Viegi, V. Brusasco, R.O. Crapo, F. Burgos, R. Casaburi, et al.
Interpretative strategies for lung function tests.
Eur Respir J, 26 (2005), pp. 948-968
[36.]
B.T. Kitch, A.D. Paltiel, K.M. Kuntz, D.W. Dockery, J.P. Schouten, S.T. Weiss, et al.
A single measure of FEV1 is associated with risk of asthma attacks in long-term followup.
Chest, 126 (2004), pp. 1875-1882
[37.]
F.W. Dekker, A.C. Schrier, P.J. Sterk, J.H. Dijkman.
Validity of peak expiratory flow measurement in assessing reversibility of airflow obstruction.
Thorax., 47 (1992), pp. 162-166
[38.]
K. Phillips, J. Oborne, S. Lewis, T.W. Harrison, A.E. Tattersfield.
Time course of action of two inhaled corticosteroids, fluticasone propionate and budesonide.
Thorax, 59 (2004), pp. 26-30
[39.]
H.K. Reddel, C.M. Salome, J.K. Peat, A.J. Woolcock.
Which index of peak expiratory flow is most useful in the management of stable asthma?.
Am J Respir Crit Care Med, 151 (1995), pp. 1320-1325
[40.]
H.M. Boezen, J.P. Schouten, D.S. Postma, B. Rijcken.
Distribution of peak expiratory flow variability by age, gender and smoking habits in a random population sample aged 20-70 yrs.
Eur Respir J, 7 (1994), pp. 1814-1820
[41.]
D.W. Cockcroft.
Bronchoprovocation methods: direct challenges.
Clin Rev Allergy Immunol, 24 (2003), pp. 19-26
[42.]
M. Van den Berge, R.J. Meijer, H.A. Kerstjens, D.M. de Reus, G.H. Koëter, H.F. Kauffman, D.S. Postma.
PC20 adenosine 5’–monophosphate is more closely associated with airway inflammation in asthma than PC20 methacholine.
Am J Respir Crit Care Med, 163 (2001), pp. 1546-1550
[43.]
S.D. Anderson, J. Brannan, J. Spring, et al.
A new method for bronchialprovocation testing in asthmatic subjects using a dry powder of mannitol.
Am J Respir Crit Care Med, 156 (1997), pp. 758-765
[44.]
R.O. Crapo, R. Casaburi, A.L. Coates, P.L. Enright, J.L. Hankinson, C.G. Irvin, et al.
Guidelines for methacholine and exercise challenge testing.
Am J Respir Crit Care Med, 161 (2000), pp. 309-329
[45.]
D.W. Cockcroft, K.Y. Murdock, B.A. Berscheid, B.P. Gore.
Sensitivity and specificity of histamine PC20 determination in a random selection of young college students.
J Allergy Clin Immunol, 89 (1992), pp. 23-30
[46.]
ATS/ERS2005. American Thoracic Society/European Respiratory Society.
Recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide.
Am J Respir Crit Care Med, 171 (2005), pp. 912-930
[47.]
D.R. Taylor, M.W. Pijnenburg, A.D. Smith, J.C. De Jongste.
Exhaled nitric oxide measurements: clinical application and interpretation.
Thorax, 61 (2006), pp. 817-827
[48.]
L.J. Dupont, M.G. Demedts, G.M. Verleden.
Prospective evaluation of the validity of exhaled nitric oxide for the diagnosis of asthma.
Chest, 123 (2003), pp. 751-756
[49.]
A.D. Smith, J.O. Cowan, S. Filsell, C. McLachlan, G. Monti-Sheehan, P. Jackson, et al.
Diagnosing asthma: comparisons between exhaled nitric oxide measurements and conventional tests.
Am J Respir Crit Care Med, 169 (2004), pp. 473-478
[50.]
L.B. Bacharier, R.C. Strunk, D. Mauger, D. White, R.F. Lemanske, C.A. Sorkness.
Classifying Asthma Severity in Children: Mismatch Between Symptoms, Medication Use, and Lung Function.
Am J Respir Crit Care Med, 170 (2004), pp. 426-432
[51.]
M.R. Miller, J. Hankinson, V. Brusasco, F. Burgos, R. Casaburi, A. Coates.
ATS/ERS TASK force: standardisation of lung function testing. Standardisation of spirometry.
Eur Respir J, 26 (2005), pp. 319-338
[52.]
D. Ownby, E. Peterson, C. Johnson.
Factors Related to Methacholine Airway Responsiveness in Children.
Am J Respir Crit Care Med, 161 (2000), pp. 1578-1583
[53.]
A.L. Parker, M. Abu-Hijleh, F.D. McCool.
Ratio Between Forced Expiratory Flow Between 25% and 75% of Vital Capacity and FVC Is a Determinant of Airway Reactivity and Sensitivity to Methacholine.
Chest, 124 (2003), pp. 63-69
[54.]
J.L. Faul, E.A. Demers, C.M. Burke, L.W. Poulter.
The reproducibility of repeat measures of airway inflammation in stable atopic asthma.
Am J Respir Crit Care Med, 160 (1999), pp. 1457-1461
[55.]
O. Asensio de la Cruz, A. Cordón Martínez, J. Elorz Lambarri, A. Moreno Galdó, J.R. Villa Asensi, Grupo de Técnicas de la Sociedad Española de Neumología Pediátrica.
Estudio de la funcion pulmónar en el paciente colaborador.Parte II.
An Pediatr (Barc.), 66 (2007), pp. 518-530
[56.]
E.G. Pérez-Yarza, J.R. Villa, N. Cobos, M. Navarro, A. Salcedo, C. Martín, et al.
Espirometría forzada en preescolares sanos bajo las recomendaciones de la ATS/ERS: estudio CANDELA.
An Pediatr (Barc), 70 (2009), pp. 3-11
[57.]
S. Stanojevic, A. Wade, S. Lum, J. Stocks.
Reference equations for pulmonary function tests in preschool children: A review.
Pediatric Pulmonology, 42 (2007), pp. 962-972
[58.]
N. Beydon, S.D. Davis, E. Lombardi, J.L. Allen, H. Arets, P. Aurora, On behalf of the American Thoracic Society/European Respiratory Society Working Group on Infant and Young Children Pulmonary Function Testing, et al.
An Official American Thoracic Society/European Respiratory Society Statement: Pulmonary Function Testing in Preschool Children.
Am J Respir Crit Care Med, 175 (2007), pp. 1304-1345
[59.]
N. Cobos Barroso, E.G. Pérez-Yarza, O. Sardón Prado, C. Reverté Bover, S. Gartner, J. Korta Murua.
Óxido nítrico exhalado en niños: un indicador no invasivo de la inflamación de las vías aereas.
Arch Bronconeumol, 44 (2008), pp. 41-51
[60.]
T.J. Warke, P.S. Fitch, V. Brown, R. Taylor, J.D. Lyons, M. Ennis, et al.
Exhaled nitric oxide correlates with airway eosinophils in childhood asthma.
Thorax, 57 (2002), pp. 383-387
[61.]
M.W. Pijnenburg, W. Hofhuis, W.C. Hop, J.C. De Jonste.
Exhaled nitric oxide predicts asthma relapse in children with clinical asthma remission.
Thorax, 60 (2005), pp. 215-218
[62.]
L. Heinzerling, A.J. Frew, C. Bindslev-Jensen, S. Bonini, J. Bousquet, M. Bresciani, et al.
Standard skin prick testing and sensitization to inhalant allergens across Europe – a survey from GA2LEN network.
Allergy, 60 (2005), pp. 1287-1300
[63.]
E.Y. Chan, I. Dundas, P.D. Bridge, M.J. Healy, S.A. McKenzie.
Skin-prick testing as a diagnostic aid for childhood asthma.
Pediatr Pulmonol, 39 (2005), pp. 558-562
[64.]
J. Oppenheimer, H.S. Nelson.
Skin testing.
Ann Allergy Asthma Immunol, 96 (2006), pp. S6-S12
[66.]
A. Simpson, L. Soderstrom, S. Ahlstedt, C.S. Murray, A. Woodcock, A. Custovic.
IgE antibody quantification and the probability of wheeze in preschool children.
J Allergy Clin Immunol, 116 (2005), pp. 744-749
[67.]
J.M. Tschopp, D. Sistek, C. Schindler, P. Leuenberger, A.P. Perruchoud, B. Wuthrich, et al.
Current allergic asthma and rhinitis: diagnostic efficiency of three commonly used atopic markers (IgE, skin prick tests, and Phadiatop). Results from 8329 randomized adults from the SAPALDIA Study. Swiss Study on Air Pollution and Lung Diseases in Adults.
Allergy, 53 (1998), pp. 608-613
[68.]
J. Beach, K. Russell, S. Blitz, N. Hooton, C. Spooner, C. Lemiere, et al.
A systematic review of the diagnosis of occupational asthma.
Chest, 131 (2007), pp. 569-578
[69.]
GINA 2002. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention: NHLBI/WHO Report. Bethesda: National Institutes of Health, National Heart, Lung, and Blood Institute, 2002. Publication 02-3659.
[70.]
NAEPP 2002. Nacional Asthma Education and Prevention Program. Guidelines for the diagnosis and management of asthma: Expert Panel Report 2. Bethesda: National Institutes of Health, National Heart, Lung, and Blood Institute, 2002. Publication 97-4051.
[71.]
V. Plaza, F.J. Alvarez, P. Casan, N. Cobos, A. Lopez Viña, En calidad de Comité Ejecutivo de la GEMA y en representación del grupo de redactores, et al.
Guía Española para el Manejo del Asma (GEMA 2003).
Arch Bronconeumol, 39 (2003), pp. 1-42
[72.]
E.D. Bateman.
Severity and control of severe asthma.
J Allergy Clin Immunol, 117 (2006), pp. 519-521
[73.]
S.W. Stoloff, H.A. Boushey.
Severity, control, and responsiveness in asthma.
J Allergy Clin Immunol, 117 (2006), pp. 544-548
[74.]
D.W. Cockcroft, V.A. Swystun.
Asthma control versus asthma severity.
J Allergy Clin Immunol, 98 (1996), pp. 1016-1018
[75.]
D.R. Taylor, E.D. Bateman, L.P. Boulet, H.A. Boushey, W.W. Busse, T.B. Casale, et al.
A new perspective on concepts of asthma severity and control.
Eur Respir J, 32 (2008), pp. 545-554
[76.]
M.L. Osborne, W.M. Vollmer, K.L. Pedula, J. Wilkins, A.S. Buist, M. O’Hollaren.
Lack of correlation of symptoms with specialist-assessed long-term asthma severity.
Chest, 115 (1999), pp. 85-91
[77.]
E.D. Bateman, H.A. Boushey, J. Bousquet, W.W. Busse, T.J. Clark, R.A. Pauwels, et al.
Can guidelinedefined asthma control be achieved? The Gaining Optimal Asthma ControL study.
Am J Respir Crit Care Med, 170 (2004), pp. 836-844
[78.]
R.A. Nathan, C.A. Sorkness, M. Kosinski, M. Schatz, J.T. Li, P. Marcus, et al.
Development of the asthma control test: a survey for assessing asthma control test.
J allergy Clin Immunol, 113 (2004), pp. 59-65
[79.]
J.M. Vega, X. Badia, C. Badiola, A. López-Viña, J.M. Olaguibel, C. Picado, Covalair Investigator Group, et al.
Validation of the Spanish version of the Asthma Control Test (ACT).
J Asthma, 44 (2007), pp. 867-872
[80.]
E.F. Juniper, P.M. O’Byrne, G.H. Guyatt, P.J. Ferrie, D.R. King.
Development and validation of a questionnaire to measure asthma control.
Eur Respir J, 14 (1999), pp. 902-907
[81.]
C. Picado, C. Badiola, N. Perulero, J. Sastre, J.M. Olaguíbel, A. López Viña, J.M. Vega, Covalair Investigator Group.
Validation of the Spanish version of the Asthma Control Questionnaire.
Clin Ther, 30 (2008), pp. 1918-1931
[82.]
E.F. Juniper, M.E. Wisniewski, F.M. Cox, A.H. Emmett, K.E. Nielsen, P.M. O’Byrne.
Relationshipbetween quality of life and clinical status in asthma: a factor analysis.
Eur Respir J, 23 (2004), pp. 287-291
[83.]
E.F. Juniper, G.H. Guyatt, D.H. Feeny, P.J. Ferrie, L.E. Griffith, M. Townsend.
Measuring quality of life in children with asthma.
Qual Life Res, 5 (1996), pp. 35-46
[84.]
E.F. Juniper, G.H. Guyatt, F.M. Cox, P.J. Ferrie, D.R. King.
Development and validation of the Mini Asthma Quality of Life Questionnaire.
Eur Respir J, 14 (1999), pp. 32-38
[85.]
A.L. Fuhlbrigge, B.T. Kitch, A.D. Paltiel, et al.
FEV1 is associated with risk of asthma attacks in a pediatric population.
J Allergy Clin Immunol, 107 (2001), pp. 61-67
[86.]
H.L. Petsky, C.J. Cates, A.M. Li, J.A. Kynaston, C. Turner, A.B. Chang.
Tailored interventions based on exhaled nitric oxide versus clinical symptoms for asthma in children and adults.
Cochrane Database Syst Rev, 2 (2008),
[87.]
S.J. Szefler, H. Mitchell, C.A. Sorkness, P.J. Gergen, G.T. O’Connor, W.J. Morgan, et al.
Management of asthma based on exhaled nitric oxide in addition to guidelinebased treatment for innercity adolescents and young adults: a randomised controlled trial.
Lancet, 372 (2008), pp. 1065-1072
[88.]
H. Petsky, J. Kynaston, C. Turner, A. Li, C. Cates, T. Lasserson, et al.
Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults.
Cochrane Database Syst Rev, 2 (2007),
[89.]
E.G. Perez-Yarza, X. Badia, C. Badiola, N. Cobos, J. Garde, M. Ibero, On behalf of the CAN Investigator Group, et al.
Development and validation of a questionnaire to assess asthma control in pediatrics.
Pediatr Pulmonol, 44 (2009), pp. 54-63
[90.]
L.P. Boulet, A. Becker, D. Berubé, R. Beveridge, P. Ernst, On behalf of the Canadian Asthma Consensus Group.
Sumary of recommendations from the Canadians Asthma Consensus report.
CMAJ, 161 (1999), pp. S1-S12
[91.]
P.G. Gibson, H. Powell, F.M. Ducharme.
Differential effects of maintenance longacting betaagonist and inhaled corticosteroid on asthma control and asthma exacerbations.
J Allergy Clin Immunol, 119 (2007), pp. 344-350
[92.]
E.D. Bateman, L. Jacques, C. Goldfrad, T. Atienza, T. Mihaescu, M. Duggan.
Asthma control can be maintained when fluticasone propionate/salmeterol in a single inhaler is stepped down.
J Allergy Clin Immunol, 117 (2006), pp. 563-570
[94.]
R.A. Tan, S.L. Spector.
Exerciseinduced asthma: diagnosis and management.
Ann Allergy Asthma Immunol, 89 (2002), pp. 226-235
[95.]
N.P. Adams, J.B. Bestall, R. Malouf, T.J. Lasserson, P.W. Jones.
Inhaled beclomethasone versus placebo for chronic asthma.
Cochrane Database Syst Rev, 1 (2005),
[96.]
N.P. Adams, J.C. Bestall, T.J. Lasserson, P.W. Jones, C. Cates.
Fluticasone versus placebo for chronic asthma in adults and children.
Cochrane Database Syst Rev, 4 (2005),
[97.]
M.S. Koh, L.B. Irving.
Evidence-based pharmacologic treatment for mild asthma.
Int J Clin Pract, 61 (2007), pp. 1375-1379
[98.]
H.K. Reddel, E.G. Belousova, G.B. Marks, C.R. Jenkins.
Does continuous use of inhaled corticosteroids improve outcomes in mild asthma? A doubleblind randomised controlled trial.
Prim Care Respir J, 17 (2008), pp. 39-45
[99.]
H.A. Boushey, C.A. Sorkness, T.S. King, S.D. Sullivan, J.V. Fahy, et al.
Daily versus asneeded corticosteroids for mild persistent asthma.
N Engl J Med, 352 (2005), pp. 1519-1528
[100.]
R.S. Zeiger, S.R. Bird, M.S. Kaplan, M. Schatz, D.S. Pearlman, E.J. Orav, et al.
Short-term and long-term asthma control in patients with mild persistent asthma receiving montelukast or fluticasone: a randomized controlled trial.
Am J Med, 118 (2005), pp. 649-657
[101.]
N.C. Barnes, C.J. Miller.
Effect of leukotriene receptor antagonist therapy on the risk of asthma exacerbations in patients with mild to moderate asthma: an integrated analysis of zafirlukast trials.
Thorax, 55 (2000), pp. 478-483
[102.]
S.P. Peters, N. Anthonisen, M. Castro, J.T. Holbrook, C.G. Irvin, ALA, et al.
American Lung Association Asthma Clinical Research Centers, Randomized comparison of strategies for reducing treatment in mild persistent asthma.
N Engl J Med, 356 (2007), pp. 2027-2039
[103.]
W.W. Busse, T.B. Casale, M.S. Dykewicz, E.O. Meltzer, S.R. Bird, C.M. Hustad, et al.
Efficacy of montelukast during the allergy season in patients with chronic asthma and seasonal aeroallergen sensitivity.
Ann Allergy Asthma Immunol, 96 (2006), pp. 60-68
[104.]
D.B. Price, A. Swern, C.A. Tozzi, G. Philip, P. Polos.
Effect of montelukast on lung function in asthma patients with allergic rhinitis: analysis from the COMPACT trial.
Allergy, 61 (2006), pp. 737-742
[105.]
P.M. O’Byrne, P.J. Barnes, R. Rodriguez Roisin, E. Runnerstrom, T. Sandstrom, K. Svensson, et al.
Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial.
Am J Respir Crit Care Med, 164 (2001), pp. 1392-1397
[106.]
R. Dahl, B.B. Larsen, P. Venge.
Effect of long-term treatment with inhaled budesonide or theophylline on lung function, airway reactivity and asthma symptoms.
Respir Med, 96 (2002), pp. 432-438
[107.]
P. Sullivan, S. Bekir, Z. Jaffar, C. Page, P. Jeffery, J. Costello.
Antiinflammatory effects of low-dose oral theophylline in atopic asthma.
Lancet, 343 (1994), pp. 1006-1008
[108.]
T. Dudley, S. Parker, R. Baldwin.
Clinical inquiries. Is nedocromil effective in preventing asthmatic attacks in patients with asthma?.
J Fam Pract, 53 (2004), pp. 927-928
[109.]
A. Woolcock, B. Lundback, N. Ringdal, L.A. Jacques.
Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids.
Am J Respir Crit Care Med, 153 (1996), pp. 1481-1488
[110.]
R.A. Pauwels, C.G. Lofdahl, D.S. Postma, A.E. Tattersfield, P. O’Byrne, P.J. Barnes, et al.
Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group.
N Engl J Med, 337 (1997), pp. 1405-1411
[111.]
S. Shrewsbury, S. Pyke, M. Britton.
Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA).
BMJ, 320 (2000), pp. 1368-1373
[112.]
I.R. Greenstone, M.N. Ni Chroinin, V. Masse, A. Danish, H. Magdalinos, X. Zhang, et al.
Combination of inhaled long-acting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma.
Cochrane Database Syst Rev, 4 (2005),
[113.]
M. Masoli, M. Weatherall, S. Holt, R. Beasley.
Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma.
Thorax, 60 (2005), pp. 730-734
[114.]
R. Scicchitano, R. Aalbers, D. Ukena, A. Manjra, L. Fouquert, S. Centanni, et al.
Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma.
Curr Med Res Opin, 20 (2004), pp. 1403-1418
[115.]
P.M. O’Byrne, H. Bisgaard, P.P. Godard, M. Pistolesi, M. Palmqvist, Y. Zhu, et al.
Budsonide/formoterol combination therapy as both maintenance and reliever medication in asthma.
Am J Respir Crit Care Med, 171 (2005), pp. 129-136
[116.]
K.F. Rabe, T. Atienza, P. Magyar, P. Larsson, C. Jorup, U.G. Lalloo.
Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomized controlled, double-blind study.
Lancet, 368 (2006), pp. 744-753
[117.]
K.F. Rabe, E. Pizzichini, B. Stallberg, S. Romero, A.M. Balanzat, T. Atienza, et al.
Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial.
Chest, 129 (2006), pp. 246-256
[118.]
C. Vogelmeier, A. D’Urzo, R. Pauwels, J.M. Merino, M. Jaspal, S. Boutet, et al.
Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option?.
Eur Respir J, 26 (2005), pp. 819-828
[119.]
J. Bousquet, L.P. Boulet, M.J. Peters, H. Magnussen, J. Quiralte, N.E. Martínez-Aguilar, et al.
Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone.
Respir Med, 101 (2007), pp. 2437-2446
[120.]
P. Kuna, M.J. Peters, A.I. Manjra, C. Jorup, I.P. Naya, N.E. Martínez-Jimenez, et al.
Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations.
Int J Clin Pract, 61 (2007), pp. 725-736
[121.]
S.J. Szefler, R.J. Martin, T.S. King, H.A. Boushey, R.M. Cherniack, V.M. Chinchilli, et al.
Significant variability in response to inhaled corticosteroids for persistent asthma.
J Allergy Clin Immunol, 109 (2002), pp. 410-418
[122.]
H. Powell, P.G. Gibson.
Initial starting dose of inhaled corticosteroids in adults with asthma: a systematic review.
Thorax, 59 (2004), pp. 1041-1045
[123.]
W.R. Pieters, K.K. Wilson, H.C. Smith, J.J. Tamminga, S. Sondhi.
Salmeterol/fluticasone propionate versus fluticasone propionate plus montelukast: a cost-effective comparison for asthma.
Treat Respir Med, 4 (2005), pp. 129-138
[124.]
S. Joos, A. Miksch, J. Szecsenyi, B. Wieseler, U. Grouven, T. Kaiser, et al.
Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review.
Thorax, 63 (2008), pp. 453-462
[125.]
F.S. Ram, C.J. Cates, F.M. Ducharme.
Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma.
Cochrane Database Syst Rev, 25 (2005),
[126.]
M. Ni Chroinin, I.R. Greenstone, A. Danish, H. Magdolinos, V. Masse, X. Zhang, et al.
Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma.
Cochrane Database Syst Rev, 4 (2005),
[127.]
J.H. Toogood, J.C. Baskerville, B. Jennings, N.M. Lefcoe, S.A. Johansson.
Influence of dosing frequency and schedule on the response of chronic asthmatics to the aerosol steroid, budesonide.
J Allergy Clin Immunol, 70 (1982), pp. 288-298
[128.]
M. Tonelli, M. Zingoni, E. Bacci, F.L. Dente, A. Di Franco, D. Giannini, et al.
Short-term effect of the addition of leukotriene receptor antagonists to the current therapy in severe asthmatics.
Pulm Pharmacol Ther, 16 (2003), pp. 237-240
[129.]
H. Inoue, M. Komori, T. Matsumoto, S. Fukuyama, M. Matsumura, T. Nakano, et al.
Effects of salmeterol in patients with persistent asthma receiving inhaled corticosteroid plus theophylline.
Respiration, 74 (2007), pp. 611-616
[130.]
M. Humbert, W. Berger, G. Rapatz, F. Turk.
Add-on omalizumab improves day-today symptoms in inadequately controlled severe persistent allergic asthma.
Allergy, 63 (2008), pp. 592-596
[131.]
M. Humbert, R. Beasley, J. Ayres, R. Slavin, J. Hebert, J. Bousquet, et al.
Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.
Allergy, 60 (2005), pp. 309-316
[132.]
W. Busse, J. Corren, B.Q. Lanier, M. McAlary, A. Fowler-Taylor, G.D. Cioppa, N. Gupta, et al.
Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.
J Allergy Clin Immunol, 108 (2001), pp. 184-190
[133.]
W.W. Busse, M. Massanari, F. Kianifard, G.P. Geba.
Effect of omalizumab on the need for rescue systemic corticosteroid treatment in patients with moderate-to-severe persistent IgE-mediated allergic asthma: a pooled analysis.
Curr Med Res Opin, 23 (2007), pp. 2379-2386
[134.]
B. Mash, A. Bheekie, P.W. Jones.
Inhaled vs oral steroids for adults with chronic asthma.
Cochrane Database Syst Rev, (2000), pp. 2
[135.]
R. Polosa.
An overview of chronic severe asthma.
Intern Med J, 38 (2008), pp. 190-198
[136.]
S.P. Newman, S.W. Clarke.
Therapeutic aerosols 1–physical and practical considerations.
Thorax, 38 (1983), pp. 881-886
[137.]
S.W. Clarke, S.P. Newman.
Therapeutic aerosols 2–Drugs available by the inhaled route.
Thorax, 39 (1984), pp. 1-7
[138.]
J. Giner, L.V. Basualdo, P. Casan, C. Hernández, V. Macián, I. Martínez, et al.
Normativa sobre la utilización de fármacos inhalados. Recomendaciones SEPAR.
Arch Bronconeumol, 36 (2000), pp. 34-43
[139.]
D.R. Hess.
Aerosol delivery devices in the treatment of asthma.
Respir Care, 53 (2008), pp. 699-723
[140.]
Y.S. Cheng, C.S. Fu, D. Yazzie, Y. Zhou.
Respiratory deposition patterns of salbutamol pMDI with CFC and HFA-134a formulations in a human airway replica.
J Aerosol Med, 14 (2001), pp. 255-266
[141.]
P.H. Brown, A.P. Greening, G.K. Crompton.
Large volume spacer devices and the influence of high dose beclomethasone dipropionate on hypothalamo-pituitaryadrenal axis function.
Thorax, 48 (1993), pp. 233-238
[142.]
S.P. Newman, M.T. Newhouse.
Effect of add-on devices for aerosol drug delivery: deposition studies and clinical aspects.
J Aerosol Med, 9 (1996), pp. 55-70
[143.]
S.P. Newman.
Spacer devices for metered dose inhalers.
Clin Pharmacokinet, 43 (2004), pp. 349-360
[144.]
V. Plaza, J. Sanchis.
Medical personnel and patient skill in the use of metered dose inhalers: a multicentric study. CESEA Group.
Respiration, 65 (1998), pp. 195-198
[145.]
J. Giner, V. Macian, C. Hernandez, E.D.E.N. Grupo, et al.
Multicenter prospective study of respiratory patient education and instruction in the use of inhalers (EDEN study).
Arch Bronconeumol, 38 (2002), pp. 300-305
[146.]
P. Lange, J. Parner, J. Vestbo, P. Schnohr, G. Jensen.
A 15-year followup study of ventilatory function in adults with asthma.
N Engl J Med, 339 (1998), pp. 1194-1200
[147.]
A.L. James, L.J. Palmer, E. Kicic, P.S. Maxwell, S.E. Lagan, G.F. Ryan, et al.
Decline in lung function in the Busselton Health Study: the effects of asthma and cigarette smoking.
Am J Respir Crit Care Med, 171 (2005), pp. 109-114
[148.]
C.A. Jimenez Ruiz, M. Barrueco, S. Solano, M. Torrecilla, M. Domínguez, Díaz-Maroto, et al.
Recomendaciones en el abordaje diagnóstico y terapéutico del tabaquismo. Documento de consenso.
Arch Bronconeumol, 39 (2003), pp. 35-41
[149.]
W.J. Morgan, E.F. Crain, R.S. Gruchalla, G.T. O’Connor, M. Kattan, R. Evans, et al.
Results of a home-based environmental intervention among urban children with asthma.
N Engl J Med, 351 (2004), pp. 1068-1080
[150.]
W. Phipatanakul, B. Cronin, R.A. Wood, P.A. Eggleston, M.C. Shih, L. Song, et al.
Effect of environmental intervention on mouse allergen levels in homes of inner-city Boston children with asthma.
Ann Allergy Asthma Immunol, 92 (2004), pp. 420-425
[151.]
T. Shirai, T. Matsui, K. Suzuki, K. Chida.
Effect of pet removal on pet allergic asthma.
Chest, 127 (2005), pp. 1565-1571
[152.]
R. Orriols, K. Abu, E. Alday, M.J. Cruz, J.B. Galdiz, I. Isidro, et al.
Normativa del asma ocupacional.
Arch Bronconeumol, 42 (2006), pp. 457-474
[153.]
C. Luczynska, E. Tredwell, N. Smeeton, P. Burney.
A randomized controlled trial of mite allergen-impermeable bed covers in adult mite-sensitized asthmatics.
Clin Exp Allergy, 33 (2003), pp. 1648-1653
[154.]
A. Woodcock, L. Forster, E. Matthews, J. Martin, L. Letley, M. Vickers, et al.
Medical Research Council General Practice Research Framework. Control of exposure to mite allergen and allergen-impermeable bed covers for adults with asthma.
N Engl J Med, 349 (2003), pp. 225-236
[155.]
P.C. Gotzsche, H.K. Johansen.
House dust mite control measures for asthma: systematic review.
Allergy, 63 (2008), pp. 646-659
[156.]
T. Htut, T.W. Higenbottam, G.W. Gill, R. Darwin, P.B. Anderson, N. Syed.
Eradication of house dust mite from homes of atopic asthmatic subjects: a double-blind trial.
J Allergy Clin Immunol, 107 (2001), pp. 55-60
[157.]
S. Halken, A. Host, U. Niklassen, L.G. Hansen, F. Nielsen, S. Pedersen, et al.
Effect of mattress and pillow encasings on children with asthma and house dust mite allergy.
J Allergy Clin Immunol, 111 (2003), pp. 169-176
[158.]
A. Sheikh, B. Hurwitz, Y. Shehata.
House dust mite avoidance measures for perennial allergic rhinitis.
Cochrane Database of Systematic Reviews, (2007),
[159.]
T.A.E. Platts-Mills.
Allergen avoidance in the treatment of asthma: Problems with the meta-analyses.
J Allergy Clin Immunol, 122 (2008), pp. 694-696
[160.]
V. Plaza, J. Serrano, C. Picado, J. Sanchis, High Risk Asthma Research Group.
Frequency and clinical characteristics of rapid-onset fatal and near-fatal asthma.
Eur Respir J, 19 (2002), pp. 846-852
[161.]
E. Nizankowska-Mogilnicka, G. Bochenek, L. Mastalerz, M. Swierczyfska, C. Picado, G. Scadding, et al.
EAACI/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity.
Allergy, 62 (2007), pp. 1111-1118
[162.]
J. Casadevall, P.J. Ventura, J. Mullol, C. Picado.
Intranasal challenge with aspirin in the diagnosis of aspirin intolerant asthma: evaluation of nasal response by acoustic rhinometry.
Thorax, 55 (2000), pp. 921-924
[163.]
A. Valero, M. Baltasar, E. Enrique, L. Pau, M.T. Dordal, A. Cistero, et al.
C. NSAID-sensitive patients tolerate rofecoxib.
Allergy, 57 (2002), pp. 1214-1215
[164.]
M.J. Abramson, R.M. Puy, J.M. Weiner.
Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials.
Am J Respir Crit Care Med, 151 (1995), pp. 969-974
[165.]
M.J. Abramson, R.M. Puy, J.M. Weiner.
Allergen immunotherapy for asthma.
Cochrane Database Syst Rev, 4 (2003),
[166.]
N.F. Adkinson Jr, P.A. Eggleston, D. Eney, E.O. Goldstein, K.C. Schuberth, J.R. Bacon, et al.
A controlled trial of immunotherapy for asthma in allergic children.
N Engl J Med, 336 (1997), pp. 324-331
[167.]
D.I. Bernstein, M. Wanner, L. Borish, G.M. Liss.
Immunotherapy Committee, American Academy of Allergy. Asthma and Immunology. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001.
J Allergy Clin Immunol, 113 (2004), pp. 1129-1136
[168.]
C. Moreno, J. Cuesta Herranz, L. Fernández Tavora, E. Álvarez Cuesta.
Immunotherapy safety: a prospective multi-centric monitoring study of biologically standardized therapeutic vaccines for allergic diseases.
Clin Exp Allergy, 34 (2004), pp. 527-531
[169.]
J.M. Olaguibel, M.J. Álvarez Puebla.
Efficacy of sublingual allergen vaccination for respiratory allergy in children. Conclusions from one metaanalysis.
J Investig Allergol Clin Immunol, 15 (2005), pp. 9-16
[170.]
M. Penagos, G. Passalacqua, E. Compalati, C.E. Baena-Cagnani, S. Orozco, A. Pedroza, et al.
Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age.
Chest, 133 (2008), pp. 599-609
[171.]
S.R. Durham, S.M. Walker, E.M. Varga, M.R. Jacobson, F. O’Brien, W. Noble, et al.
Longterm clinical efficacy of grasspollen immunotherapy.
N Engl J Med, 341 (1999), pp. 468-475
[172.]
L. Jacobsen, B. Niggemann, S. Dreborg, H.A. Ferdousi, S. Halken, A. Host, The PAT investigator Group, et al.
Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study.
Allergy, 62 (2007), pp. 943-948
[173.]
G.B. Pajno, G. Barberio, F. De Luca, L. Morabito, S. Parmiani.
Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A sixyear follow-up study.
Clin Exp Allergy, 31 (2001), pp. 1392-1397
[174.]
O. Abadoglu, D. Mungan, G. Pasaoglu, G. Celik, Z. Misirligil.
Influenza vaccination in patients with asthma: effect on the frequency of upper respiratory tract infections and exacerbations.
J Asthma, 41 (2004), pp. 279-283
[175.]
C. Christy, C.A. Aligne, P. Auinger, T. Pulcino, M. Weitzman.
Effectiveness of influenza vaccine for the prevention of asthma exacerbations.
Arch Dis Child, 89 (2004), pp. 734-735
[176.]
A. Sheikh, A. Alves, S. Dhami.
Pneumococcal vaccine for asthma.
Cochrane Database of Systematic Reviews, (2002),
[177.]
N.W. Johnston, M.R. Sears.
Asthma exacerbations. Epidemiology.
Thorax, 61 (2006), pp. 722-728
[178.]
D.M. Hughes, M. McLeod, B. Garner, R.B. Goldbloom.
Controlled trial of a home and ambulatory program for asthmatic children.
Pediatrics, 87 (1991), pp. 54-61
[179.]
V.T. Colland.
Learning to cope with asthma: a behavioural selfmanagement program for children.
Patient Educ Couns, 22 (1993), pp. 141-152
[180.]
J. Van der Palen, J.J. Klein, G.A. Zielhuis, C.L. van Herwaarden, E.R. Seydel.
Behavioural effect of self-treatment guidelines in a self-management program for adults with asthma.
Patient Educ Couns, 43 (2001), pp. 161-169
[181.]
Gibson PG, Powell H, Coughlan J, Wilson AJ, Abramson M, Haywood Bauman A, et al. Educación para el autocuidado y examen médico regular para adultos con asma (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2008 Número 1. Oxford: Update Software Ltd. Disponible en: http://www.updatesoftware.com.
[182.]
Powell H, Gibson PG. Opciones para la educación sobre el autocuidado para los adultos con asma (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2008, Número 1. Oxford: Update.
[183.]
M.R. Partridge.
Patient education.
Manual of asthma management, pp. 378-392
[184.]
Haynes RB, McDonald H, Garg AX et al. Interventions for helping patients to follow prescriptions for medications (Cochrane Review). 2001; 3. Oxford: Update Software.
[185.]
T.L. Creer.
Medication compliance and childhood asthma.
Developmental aspects of health compliance behavior, pp. 303-333
[186.]
P.G. Gibson, J. Coughlan, A.J. Wilson, M. Abramson, A. Bauman, M.J. Hensley, et al.
Self-management education and regular practitioner review for adults with asthma.
Cochrane Database Syst Rev, 2 (2000),
[187.]
M.J. Abramson, M.J. Bailey, F.J. Couper, J.S. Drivers, O.H. Drummer, A.B. Forbes, et al.
Are asthma medications and management related to deaths from asthma?.
Am J Respir Crit Care Med, 163 (2001), pp. 12-18
[188.]
J. Douglass, R. Aroni, D. Goeman, K. Stewart, S. Sawyer, F. Thien, et al.
A qualitative study of action plans for asthma.
BMJ, 324 (2002), pp. 1003-1005
[189.]
H.K. Reddel, G.B. Marks, C.R. Jenkins.
When can personal best peak flow be determined for asthma action plans?.
Thorax, 59 (2004), pp. 922-924
[190.]
A. Lahdensuo.
Guided self management of asthma-how to do it.
BMJ, 319 (1999), pp. 759-760
[191.]
J. Côté, D.M. Bowie, P. Robichaud, J.G. Parent, L. Battisti, L.P. Boulet.
Evaluation of two different educational interventions for adult patients consulting with an acute asthma exacerbation.
Am J Respir Crit Care Med, 163 (2001), pp. 1415-1419
[192.]
P.G. Gibson, H. Powell.
Written action plans for asthma: an evidencebased review of the key components.
Thorax, 59 (2004), pp. 94-99
[193.]
M. Castro, N.A. Zimmermann, S. Crocker, J. Bradley, C. Leven, K.B. Schechtman.
Asthma intervention program prevents readmissions in high healthcare users.
Am J Respir Crit Care Med, 168 (2003), pp. 1095-1099
[194.]
A. Borgmeyer, P.M. Gyr, P.A. Jamerson, L.D. Henry.
Evaluation of the role of the pediatric nurse practitioner in an inpatient asthma program.
J Pediatr Health Care, 22 (2008), pp. 273-281
[195.]
P.G. Woodruff, S.D. Emond, A.K. Singh, C.A. Camargo Jr.
Sudden-onset severe acute asthma: clinical features and response to therapy.
Acad Emerg Med, 5 (1998), pp. 695-701
[196.]
M.O. Turner, K. Noertjojo, S. Vedal, T. Bai, S. Crump, J.M. Fitzgerald.
Risk factors for near-fatal asthma. A casecontrol study in hospitalized patients with asthma.
Am J Respir Crit Care Med, 157 (1998), pp. 1804-1809
[197.]
I. Mitchell, S.C. Tough, L.K. Semple, F.H. Green, P.A. Hessel.
Near-fatal asthma: a population-based study of risk factors.
Chest, 121 (2002), pp. 1407-1413
[198.]
J. Serrano, V. Plaza, B. Sureda, J. De Pablo, C. Picado, S. Bardagi, et al.
Alexithymia: a relevant psychological variable in near-fatal asthma.
Eur Respir J, 28 (2006), pp. 296-302
[199.]
ALERTA 2008. Guía ALAT-SEPAR ALERTA.
America Latina y España: Recomendaciones para la Prevención y el Tratamiento de la Exacerbación Asmática.
Ed. Mayo, (2008),
[200.]
E.R. McFadden, R. Kisser, W.J. De Groot.
Acute bronchial Asthma: relations between clinical and physiological manifestations.
Engl J Med, 288 (1973), pp. 221-225
[201.]
G. Rodrigo, C. Rodrigo.
Early prediction of poor response in acute asthma patients in the emergency department.
Chest, 114 (1998), pp. 1016-1021
[202.]
D.M. Carruthers, B.D. Harrisson.
Arterial Blood gas analysis or oxygen saturation in the assessment of acute asthma?.
Thorax, 50 (1995), pp. 186-188
[203.]
G.J. Rodrigo, C. Rodrigo, J.B. Hall.
Acute asthma in adults. A review.
Chest, 125 (2004), pp. 1081-1082
[204.]
R.I. Cowre, S.G. Revitt, M.F. Underwood.
The effect of peak-flow based action plan in the prevention of exacerbation of asthma.
Chest, 112 (1997), pp. 1534-1538
[205.]
C. Reisner, A. Kotch, G. Dworkin.
Continuous versus frequent intermittent nebulization of albuterol in acute asthma: a randomized, prospective study.
Ann Allergy Asthma Immunol, 75 (1995), pp. 41-47
[206.]
C.J. Cates, J.A. Crilly, B.H. Rowe.
Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma.
Cochrane Database of Systematic Reviews, 2 (2006),
[207.]
R. Manser, D. Reid, M. Abramson.
Corticosteroids for acute severe asthma in hospitalised patients.
Cochrane Database Syst Rev, (2000), pp. 2
[208.]
T. Hasegawa, K. Ishihara, S. Takakura, H. Fujii, T. Nishimura, M. Okazaki, et al.
Duration of systemic corticosteroids in the treatment of asthma exacerbation: a randomized study.
Intern Med, 39 (2000), pp. 794-797
[209.]
B.H. Rowe, C. Spooner, F.M. Ducharme, J.A. Bretzlaff, G.W. Bota.
Corticosteroids for preventing relapse following acute exacerbation of asthma (Cochrane Review).
John Wiley & Sons Ltd, (2001),
[210.]
B.H. Rowe, C.H. Spooner, F.M. Ducharme, G.W. Bota.
Corticosteroids for preventing relapse following acute exacerbations of asthma.
Cochrane Database of Systematic Reviews, 3 (2007),
[211.]
L.M. Osman, C. Calder, D.J. Godden, J.A. Friend, L. McKenzie, J.S. Legge, et al.
A randomised trial of self-management planning for adult patients admitted to hospital with acute asthma.
Thorax, 57 (2002), pp. 869-874
[212.]
G.J. Rodrigo, M. Rodriguez-Verde, V. Peregalli, C. Rodrigo.
effects of shortterm 28% and 100% oxygen in paCO2 and peak expiratory flow rate in acute Asthma. A randomized trial.
Chest, 124 (2003), pp. 1312-1317
[213.]
C. Rodrigo, G. Rodrigo.
Therapeutic response patterns to high and cumulative doses of salbutamol in acute severe asthma.
Chest, 113 (1998), pp. 593-598
[214.]
C.A. Camargo, C.H. Spooner, B.H. Rowe.
Continuous versus intermittent beta-agonists for acute asthma.
Cochrane Database of Systematic Reviews, 4 (2003),
[215.]
A. Travers, A.P. Jones, K. Kelly, S.J. Barker, C.A. Camargo, B.H. Rowe.
Intravenous beta2-agonists for acute asthma in the emergency department.
Cochrane Database of Systematic Reviews, 1 (2001),
[216.]
A.R. Rubinfeld, R. Scicchitanow, A. Hunt, P.J. Thompson, A. van Nooten, O. Selroos.
Formoterol Turbuhaler as reliever medication in patients with acute asthma.
Eur Respir J, 27 (2006), pp. 735-741
[217.]
G.J. Rodrigo, J.A. Castro Rodríguez.
Anticholinergics in the treatment of children and adults with acute asthma: a systematic review with meta-analysis.
Thorax, 60 (2005), pp. 740-746
[218.]
B.H. Rowe, C. Spooner, F.M. Ducharme, J.A. Bretzlaff, G.W. Bota.
Early emergency department treatment of acute asthma with systemic corticosteroids.
Cochrane Database of Systematic Reviews, 1 (2001),
[219.]
G.J. Rodrigo.
Rapid effects of inhaled corticosteroids in acute asthma. An evidencebased evaluation.
Chest, 130 (2006), pp. 1301-1311
[220.]
G.J. Rodrigo, L.J. Nannini.
Is there a place for nebulized magnesium sulfate in the treatment of acute asthma? A systematic review.
Curr Ther, 1 (2006), pp. 181-185
[221.]
B.H. Rowe, J.A. Bretzlaff, C. Bourdon, G.W. Bota, C.A. Camargo.
Magnesium sulfate for treating exacerbations of acute asthma in the emergency department.
Cochrane Database of Systematic Reviews, (2000),
[222.]
K. Parameswaran, J. Belda, B.H. Rowe.
Addition of intravenous aminophylline to beta2-agonists in adults with acute asthma.
Cochrane Database of Systematic Reviews, 4 (2000),
[223.]
G. Rodrigo, C. Pollack, C. Rodrigo, B.H. Rowe.
Heliox for nonintubated acute asthma patients.
Cochrane Database of Systematic Reviews, 4 (2006),
[224.]
D.V. Tuxen.
Permissive hypercapnic ventilation.
Am J Respir Crit Care Med, 150 (1994), pp. 870-874
[225.]
L. Strauss, R. Hejal, G. Galan, L. Dixon, E.R. McFadden.
Observations of the effects of aerosolized albuterol in acute asthma.
Am J Respir Crit Care Med, 155 (1997), pp. 545-548
[226.]
A. Grunfeld, J.M. Fitzgerald.
Discharge considerations in acute asthma.
Can Respir J, 3 (1996), pp. 322-324
[227.]
Z.F. Udwadia, B.D. Harrison.
An attempt to determine the optimal duration of hospital stay following a severe attack of asthma.
J R Coll Physicians Lond, 24 (1990), pp. 112-114
[228.]
M.G. Pearson, I. Ryland, B.D. Harrison.
National audit of acute severe asthma in adults admitted to hospital. Standards of Care Committee, British Thoracic Society.
Qual Health Care, 4 (1995), pp. 24-30
[229.]
T.W. Guilbert, W.J. Morgan, R.S. Zeiger, D.T. Mauger, S.J. Boehmer, S.J. Szefler, et al.
Long-term inhaled corticosteroids in preschool children at high risk for asthma.
N. Engl. J Med, 354 (2006), pp. 1985-1997
[230.]
M. McKean, F. Ducharme.
Inhaled steroids for episodic viral wheeze of childhood.
Cochrane Database Syst Rev, 1 (2000),
[231.]
H. Bisgaard, M.N. Hermansen, L. Loland, L.B. Halkjaer, F. Buchvald.
Intermittent inhaled corticosteroids in infants with episodic wheezing.
N Engl J Med, 354 (2006), pp. 1998-2005
[232.]
A.M. Teper, C.D. Kofman, G.A. Szulman, S.M. Vidaurreta, A.F. Maffey.
Fluticasone improves pulmonary function in children under 2 years old with risk factors for asthma.
Am. J Respir Crit Care Med, 171 (2005), pp. 587-590
[233.]
S.J. Szefler, B.R. Phillips, F.D. Martinez, V.M. Chinchilli, R.F. Lemanske, R.C. Strunk, et al.
Characterization of within-subject responses to fluticasone and montelukast in childhood asthma.
J Allergy Clin Immunol, 115 (2005), pp. 233-242
[234.]
F.M. Ducharme.
Anti-leukotrienes as add-on therapy to inhaled glucocorticoids in patients with asthma: systematic review of current evidence.
BMJ, 324 (2002), pp. 1545
[235.]
F.E. Simons, J.R. Villa, B.W. Lee, A.M. Teper, B. Lyttle, G. Aristizabal, et al.
Montelukast added to budesonide in children with persistent asthma: a randomized, doubleblind, crossover study.
J Pediatr, 138 (2001), pp. 694-698
[236.]
H. Bisgaard, S. Zielen, M.L. Garcia Garcia, S.L. Johnston, L. Gilles, J. Menten, et al.
Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma.
Am J respir Crit Care Med, 171 (2005), pp. 315-322
[237.]
D.A. Straub, A. Moeller, S. Minocchieri, J. Hamacher, F.H. Sennhauser, G.L. Hall.
The effect of montelukast on lung function and exhaled nitric oxide in infants with early childhood asthma.
Eur Respir J, 25 (2005), pp. 289-294
[238.]
J.C. Van der Wouden, M.J. Tasche, R.M. Bernsen, J.H. Uijen, J.C. De Jongste, F.M. Ducharme.
Inhaled sodium cromoglycate for asthma in children.
Cochrane Database Syst Rev, (2003),
[239.]
H. Bisgaard.
Effect of long-acting beta2 agonists on exacerbation rates of asthma in children.
Pediatr. Pulmonol, 36 (2003), pp. 391-398
[240.]
H. Bisgaard, P. Le Roux, D. Bjâmer, A. Dymek, J.H. Vermeulen, C. Hultquist.
Budesonide/Formoterol Maintenance Plus Reliever Therapy. A new strategy in pediatric asthma.
Chest, 130 (2006), pp. 1733-1743
[241.]
G.J. Rodrigo, V. Plaza, L. García-Marcos, J.A. Castro Rodriguez.
Safety of regular use of long-acting beta agonists as monotherapy or added to inhaled corticosteroids in asthma: a systematic review with meta-analysis.
Pulmonary Pharmacology and Therapeutics, 22 (2009), pp. 9-19
[242.]
P. Seddon, A. Bara, F.M. Ducharme, T.J. Lasserson.
Oral xanthines as maintenance treatment for asthma in children.
Cochrane Database Syst Rev, (2006),
[243.]
S. Walker, M. Monteil, K. Phelan, T.J. Lasserson, E.H. Walters.
Anti- IgE for chronic asthma in adults and children.
Cochrane Database Syst Rev, (2006),
[244.]
H. Powell, P.G. Gibson.
High dose versus low dose inhaled corticosteroid as initial starting dose for asthma in adults and children.
Cochrane Database of Systematic Reviews, 4 (2003),
[245.]
M. Ni Chroinin, I.I.G. Greenstone, F. Ducharme.
Addition of inhaled longacting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults.
Cochrane Database of Systematic Reviews, 4 (2004),
[246.]
F. Ducharme, F. di Salvio.
Antileukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children.
Cochrane Database of Systematic Reviews, 1 (2004),
[247.]
S.R. Smith, J.D. Baty, D. Hodge.
Validation of the pulmonary score: An asthma severity score for children.
Acad Emerg Med, 9 (2002), pp. 99-104
[248.]
R.O. Wright, K.A. Santucci, G.D. Jay, D.W. Steele.
Evaluation of pre– and postreatment pulse oximetry in acute childhood asthma.
Acad Emerg Med, 4 (1997), pp. 114-117
[249.]
C.F. Robertson, F. Smith, R. Beck, H. Levison.
Response to frequent low doses of nebulized salbutamol in acute asthma.
J Pediatr, 106 (1985), pp. 672-674
[250.]
J.A. Castro-Rodriguez, G.J. Rodrigo.
Beta-agonist through metered-dose inhaler with valved holding chamber versus nebulizer for acute exacerbation of wheezing or asthma in children under 5 years of age: A systematic review with meta-analysis.
J Ped, 145 (2004), pp. 172-177
[251.]
L. Rubilar, J.A. Castro-Rodriquez, G. Girardi.
Randomized trial of salbutamol via metered-dose inhaler with spacer versus nebulizer for acute wheezing in children less than 2 years of age.
Pediatr Pulmonol, 29 (2000), pp. 264-269
[252.]
H. Khine, S.M. Fuchs, A.L. Saville.
Continuous vs intermittent nebulized albuterol for emergency management of asthma.
Acad Emerg Med, 3 (1996), pp. 1019-1024
[253.]
L.H. Plotnick, F.M. Ducharme.
Combined inhaled anticholinergic agents and beta-2 agonists for initial treatment of acute asthma in children (Cochrane Review).
John Wiley & Sons Ltd, (2001),
[254.]
M.L. Everard, A. Bara, M. Kurian, T.M. Elliot, F. Ducharme.
Anticholinergic drugs for wheeze in children under the age of two years (Cochrane Review).
John Wiley & Sons Ltd, (2001),
[255.]
J.M. Becker, A. Arora, R.J. Scarfone, N.D. Spector, M.E. Fontana-Penn, E. Gracely, et al.
Oral versus intravenous corticosteroids in children hospitalized with asthma.
J Allergy Clin Immunol, 103 (1999), pp. 586-590
[256.]
P.L. Barnett, G.L. Caputo, M. Bassin, N. Kuppermann.
Intravenous versus oral corticosteroids in the management of acute asthma in children.
Ann Emerg Med, 29 (1997), pp. 212-217
[257.]
S. Schuh, J. Reisman, M. Alshehri, A. Dupuis, M. Corey, R. Arsenault, et al.
A comparison of inhaled fluticasone and oral prednisone for children with severe acute asthma.
N Engl J Med, 343 (2000), pp. 689-694
[258.]
S. Schuh, P.T. Dick, D. Stephens, M. Hartley, S. Khaikin, L. Rodríguez, et al.
High-dose inhaled fluticasone does not replace oral prednisolone in children with mild to moderate acute asthma.
Pediatrics, 118 (2006), pp. 644-650
[259.]
A.K. Nakanishi, A.K. Klasner, B.K. Rubin.
A randomized controlled trial of inhaled flunisolide in the management of acute asthma in children.
Chest, 124 (2003), pp. 790-794
[260.]
G.C. Geelhoed, L.I. Landau, P.N. Le Souef.
Evaluation of SaO2 as a predictor of outcome in 280 children presenting with acute asthma.
Ann Emerg Med, 23 (1994), pp. 1236-1241
[261.]
P. Bradding, I. Rushby, J. Scullion, M.D. Morgan.
As-required versus regular nebulized salbutamol for the treatment of acute severe asthma.
Eur Respir J, 13 (1999), pp. 290-294
[262.]
S. Kayani, D.C. Shannon.
Adverse behavioral effects of treatment for acute exacerbation of asthma in children: a comparison of two doses of oral steroids.
Chest, 122 (2002), pp. 624-628
[263.]
InternationalRhinitisManagement-WorkingGroup.
International Consensus Report on Diagnosis and Management of Rhinitis.
Allergy, 49 (1994), pp. 1-34
[264.]
W. Fokkens, V. Lund, J. Mullol, EPPo. R. a. N. P. Group.
European Position Paper on Rhinosinusitis and Nasal Polyps 2007.
Rhinology, (2008), pp. 1-111
[265.]
S.G. Johansson, T. Bieber, R. Dahl, P.S. Friedmann, B.Q. Lanier, R.F. Lockey, et al.
Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.
J Allergy Clin Immunol, 113 (2004), pp. 832-836
[266.]
J. Bousquet, N. Khaltaev, A.A. Cruz, J. Denburg, W.J. Fokkens, A. Togias, et al.
Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 Update (in collaboration with the World Health Organization, GA2LEN* and AllerGen**).
Allergy, 63 (2008), pp. 8-160
[267.]
J. Bousquet, P. van Cauwenberge, N. Khaltaev.
Allergic rhinitis and its impact on asthma.
J Allergy Clin Immunol, 108 (2001), pp. S147-S334
[268.]
G. Ciprandi, I. Cirillo, A. Vizzaccaro, M. Tosca, G. Passalacqua, E. Pallestrini, et al.
Seasonal and perennial allergic rhinitis: is this classification adherent to real life?.
Allergy, 60 (2005), pp. 882-887
[269.]
V. Bauchau, S.R. Durham.
Epidemiological characterization of the intermittent and persistent types of allergic rhinitis.
Allergy, 60 (2005), pp. 350-353
[270.]
A. Valero, M. Ferrer, J. Sastre, A.M. Navarro, L. Monclus, E. Marti-Guadaño, et al.
A new criterion by which to discriminate between patients with moderate allergic rhinitis and patients with severe allergic rhinitis based on the Allergic Rhinitis and its Impact on Asthma severity items.
J Allergy Clin Immunol, 120 (2007), pp. 359-365
[271.]
V. Bauchau, S.R. Durham.
Prevalence and rate of diagnosis of allergic rhinitis in Europe.
Eur Respir J, 24 (2004), pp. 758-764
[272.]
C. Pereira, A. Valero, C. Loureiro, I. Davila, C. Martínez-Cócera, C. Murio, et al.
Iberian study of aeroallergens sensitisation in allergic rhinitis.
Eur Ann Allergy Clin Immunol, 38 (2006), pp. 186-194
[273.]
A. Rinitis Navarro.
Alergológica 2005. Factores epidemiológicos, clínicos y socioeconómicos, de las enfermedades alérgicas en España.
Luzan 5 S.A. de ediciones, (2006),
[274.]
B. Bjorksten, T. Clayton, P. Ellwood, A. Stewart, D. Strachan.
Worldwide time trends for symptoms of rhinitis and conjunctivitis: Phase III of the International Study of Asthma and Allergies in Childhood.
Pediatr Allergy Immunol, 19 (2008), pp. 110-124
[275.]
K. Gendo, E.B. Larson.
Evidencebased diagnostic strategies for evaluating suspected allergic rhinitis.
Ann Intern Med, 140 (2004), pp. 278-289
[276.]
M.J. Crobach, J. Hermans, A.A. Kaptein, J. Ridderikhoff, H. Petri, J.D. Mulder.
The diagnosis of allergic rhinitis: how to combine the medical history with the results of radioallergosorbent tests and skin prick tests.
Scand J Prim Health Care, 16 (1998), pp. 30-36
[277.]
L. Malm, R. Gerth van Wijk, C. Bachert.
Guidelines for nasal provocations with aspects on nasal patency, airflow, and airflow resistance. International Committee on Objective Assessment of the Nasal Airways, International Rhinologic Society.
Rhinology, 38 (2000), pp. 1-6
[278.]
A. Togias.
Rhinitis and asthma: evidence for respiratory system integration.
J Allergy Clin Immunol, 111 (2003), pp. 1171-1183
[279.]
B. Leynaert, C. Neukirch, S. Kony, A. Guenegou, J. Bousquet, M. Aubier, et al.
Association between asthma and rhinitis according to atopic sensitization in a population-based study.
J Allergy Clin Immunol, 113 (2004), pp. 86-93
[280.]
J.A. Castillo, J. Mullol.
Comorbilidad de rinitis y asma en España.
Arch Bronconeumol, 44 (2008), pp. 593-599
[281.]
A.M. Navarro, A. Valero, B. Julia, S. Quirze.
Coexistence of asthma and allergic rhinitis in adult patients attending clinics: ONEAIR Study.
J Investig Allergol Clin Immunol, 18 (2008), pp. 233-238
[282.]
A. Arnedo-Pena, L. García-Marcos, G. García Hernández, I. Aguinagua Ontoso, C. González Díaz, M. Morales Suárez-Varela, et al.
Time trends and geographical variations in the prevalence of symptoms of allergic rhinitis in 6-7-year-old children from eight areas of Spain according to the ISAAC.
An Pediatr (Barc.), 62 (2005), pp. 229-236
[283.]
A. Linneberg, N. Henrik Nielsen, L. Frolund, F. Madsen, A. Dirksen, et al.
The link between allergic rhinitis and allergic asthma: a prospective population-based study. The Copenhagen Allergy Study.
Allergy, 57 (2002), pp. 1048-1052
[284.]
S. Guerra, D.L. Sherrill, F.D. Martínez, R.A. Barbee.
Rhinitis as an independent risk factor for adult-onset asthma.
J Allergy Clin Immunol, 109 (2002), pp. 419-425
[285.]
J. Bousquet, S. Gaugris, V.S. Kocevar, Q. Zhang, D.D. Yin, P.G. Polos, et al.
Increased risk of asthma attacks and emergency visits among asthma patients with allergic rhinitis: a subgroup analysis of the investigation of montelukast as a partner agent for complementary therapy [corrected].
Clin Exp Allergy, 35 (2005), pp. 723-727
[286.]
D. Price, Q. Zhang, V.S. Kocevar, D.D. Yin, M. Thomas.
Effect of a concomitant diagnosis of allergic rhinitis on asthmarelated health care use by adults.
Clin Exp Allergy, 35 (2005), pp. 282-287
[287.]
V. Sazonov Kocevar, J. Thomas, L. Jonsson, E. Valovirta, F. Kristensen, D.D. Yin, et al.
Association between allergic rhinitis and hospital resource use among asthmatic children in Norway.
Allergy, 60 (2005), pp. 338-342
[288.]
M.E. Boulay, L.P. Boulet.
Lower airway inflammatory responses to repeated verylow-dose allergen challenge in allergic rhinitis and asthma.
Clin Exp Allergy, 32 (2002), pp. 1441-1447
[289.]
M. Gaga, P. Lambrou, N. Papageorgiou, N.G. Koulouris, E. Kosmas, S. Fragakis, et al.
Eosinophils are a feature of upper and lower airway pathology in nonatopic asthma, irrespective of the presence of rhinitis.
Clin Exp Allergy, 30 (2000), pp. 663-669
[290.]
P. Taramarcaz, P.G. Gibson.
Intranasal corticosteroids for asthma control in people with coexisting asthma and rhinitis.
Cochrane Database Syst Rev, 4 (2003),
[291.]
J. Bousquet, P. van Cauwenberge, N. Ait Khaled, C. Bachert, C.E. Baena-Cagnani, J. Bouchard, et al.
Pharmacologic and anti-IgE treatment of allergic rhinitis ARIA update (in collaboration with GA2LEN).
Allergy, 61 (2006), pp. 1086-1096
[292.]
G. Passalacqua, S.R. Durham.
Allergic rhinitis and its impact on asthma update: allergen immunotherapy.
J Allergy Clin Immunol, 119 (2007), pp. 881-891
[294.]
M. Pasquali, I. Baiardini, A. Rogkakou, A.M. Riccio, C. Gamalero, D. Descalzi, et al.
Canonica. Levocetirizine in persistent allergic rhinitis and asthma: effects on symptoms, quality of life and inflammatory parameters.
Clin Exp Allergy, 36 (2006), pp. 1161-1167
[295.]
G.W. Canonica, F. Tarantini, E. Compalati, M. Penagos.
Efficacy of desloratadine in the treatment of allergic rhinitis: a meta-analysis of randomized, double-blind, controlled trials.
Allergy, 62 (2007), pp. 359-366
[296.]
I. Hore, C. Georgalas, G. Scadding.
Oral antihistamines for the symptom of nasal obstruction in persistent allergic rhinitis–a systematic review of randomized controlled trials.
Clin Exp Allergy, 35 (2005), pp. 207-212
[297.]
F.E. Simons.
Advances in H1– antihistamines.
N Engl J Med, 351 (2004), pp. 2203-2217
[298.]
R. Leurs, M.K. Church, M. Taglialatela.
H1-antihistamines: inverse agonism, antiinflammatory actions and cardiac effects.
Clin Exp Allergy, 32 (2002), pp. 489-498
[299.]
C.G. Owen, A. Shahm, K. Henshaw, L. Smeeth, A. Sheikh.
Topical treatments for seasonal allergic conjunctivitis: systematic review and meta-analysis of efficacy and effectiveness.
Br J Gen Pract, 54 (2004), pp. 451-456
[300.]
J.M. Weiner, M.J. Abramson, R.M. Puy.
Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials.
BMJ, 317 (1998), pp. 1624-1629
[301.]
A. Yanez, G.J. Rodrigo.
Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with metaanalysis.
Ann Allergy Asthma Immunol, 89 (2002), pp. 479-484
[302.]
M.L. Barnes, B.T. Biallosterski, R.D. Gray, T.C. Fardon, B.J. Lipworth.
Decongestant effects of nasal xylometazoline and mometasone furoate in persistent allergic rhinitis.
Rhinology, 43 (2005), pp. 291-295
[303.]
G.J. Rodrigo, A. Yáñez.
The role of antileukotriene therapy in seasonal allergic rhinitis: a systematic review of randomized trials.
Ann Allergy Asthma Immunol, 96 (2006), pp. 779-786
[304.]
P. Borum, N. Mygind, F. Schultz Larsen.
Intranasal ipratropium: a new treatment for perennial rhinitis.
Clin Otolaryngol Allied Sci, 4 (1979), pp. 407-411
[305.]
D.E. Schuller, J.E. Selcow, T.H. Joos, P.J. Hannaway, S.R. Hirsch, H.J. Schwartz, et al.
A multicenter trial of nedocromil sodium, 1% nasal solution, compared with cromolyn sodium and placebo in ragweed seasonal allergic rhinitis.
J Allergy Clin Immunol, 86 (1990), pp. 554-561
[306.]
P. Chervinsky, T. Casale, R. Townley, I. Tripathy, S. Hedgecock, A. Fowler-Taylor, et al.
Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis.
Ann Allergy Asthma Immunol, 91 (2003), pp. 160-167
[307.]
D.R. Wilson, M.T. Lima, S.R. Durham.
Sublingual immunotherapy for allergic rhinitis: systematic review and metaanalysis.
Allergy, 60 (2005), pp. 4-12
[308.]
M.A. Calderon, B. Alves, M. Jacobson, B. Hurwitz, A. Sheikh, S. Durham.
Allergen injection immunotherapy for seasonal allergic rhinitis.
Cochrane Database Syst Rev, (2007),
[309.]
A. Custovic, R.G. Wijk.
The effectiveness of measures to change the indoor environment in the treatment of allergic rhinitis and asthma: ARIA update (in collaboration with GA(2) LEN).
Allergy, 60 (2005), pp. 1112-1115
[310.]
V.E Murphy, V.L. Clifton, P.G. Gibson.
Asthma exacerbations during pregnancy: incidence and association with adverse pregnancy outcomes.
Thorax, 61 (2006), pp. 169-176
[311.]
V. Clifton.
Maternal asthma during pregnancy and fetal outcomes: potential mechanisms and possible solutions.
Curr Opin Allergy Clin Immunol, 6 (2006), pp. 307-311
[312.]
S. Kircher, M. Schatz, L. Long.
Variables affecting asthma course during pregnancy.
Ann Allergy Asthma Immunol, 89 (2002), pp. 437-438
[313.]
K. Demissie, M.B. Breckenridge, G.G. Rhoads.
Infant and maternal outcomes in the pregnancies of asthmatic women.
Am J Respir Crit Care Med, 158 (1998), pp. 1091-1095
[314.]
V.L. Clifton, W.B. Giles, R. Smith, A.T. Bisits, P.A. Hempenstall, C.G. Kessell, et al.
Alterations of placental vascular function in asthmatic pregnancies.
Am J Respir Crit Care Med, 164 (2001), pp. 546-553
[315.]
L.N. Bakhireva, M. Schatz, K.L. Jones, C.M. Tucker, D.J. Slymen, H.S. Klonoff-Cohen, OTIS Collaborative Research Group, et al.
Fetal sex and maternal asthma control in pregnancy.
J Asthma, 45 (2008), pp. 403-407
[316.]
M. Schatz, R.S. Zeiger, C.P. Hoffman, K. Harden, A. Forsythe, L. Chilingar, et al.
Perinatal outcomes in the pregnancies of asthmatic women: a prospective controlled analysis.
Am J Respir Crit Care Med, 151 (1995), pp. 1170-1174
[317.]
P.J. Wendel, S.M. Ramin, C. Barnett-Hamm, T.F. Rowe, F.G. Cunningham.
Asthma treatment in pregnancy: a randomized controlled study.
Am J Obstet Gynecol, 175 (1996), pp. 150-154
[318.]
M. Schatz, R.S. Zeiger, K. Harden.
The safety of asthma and allergy medications during pregnancy.
J Allergy Clin Irnmunology, 100 (1997), pp. 301-306
[319.]
NAEPP 2004. National Heart, Lung, and Blood Institute; National Asthma Education and Prevention Program Asthma and Pregnancy Working Group.
NAEPP expert panel report. Managing asthma during pregnancy: recommendations for pharmacologic treatment-2004 update.
J Allergy Clin Immunol, 115 (2005), pp. 31-33
[320.]
Asthma in pregnancy.
American College of Obstetricians and Gynecologists.
Obstet Gynecol, 111 (2008), pp. 457-464
[321.]
B. Kallen, H. Rydhstroem, A. Aberg.
Congenital malformations after the use of inhaled budesonid in early pregnancy.
Obstet. Gynecol, 93 (1999), pp. 392-395
[322.]
W.F. Rayburn, B.D. Atkinson, K. Gilbert.
Short term effects of inhaled albuterol on maternal and fetal circulations.
Am J Obstet Gynecolog, 170 (1994), pp. 770-773
[323.]
L. Park-Wyllie, P. Mazzotta, A. Pastuszak, M.E. Moretti, L. Beique, L. Hunnisett, et al.
Birth defects after maternal exposure to corticosteroids: prospective cohort study and metaanalysis of epidemiological studies.
Teratology, 62 (2000), pp. 385-392
[324.]
A.E. Czeizel, M. Rockembauer.
Population based case-control study of teratogenic potential of corticosteroids.
Teratology, 56 (1997), pp. 335-340
[325.]
E. Rey, L.P. Boulet.
Asthma in pregnancy.
BMJ, 334 (2007), pp. 582-585
[327.]
A. López Viña, R. Agüero Balbín, J.L. Aller Álvarez, T. Bazús González, B.G. Cosio, A. de Diego Damiá, et al.
Normativa para el asma de control dificil.
Arch Bronconeumol, 41 (2005), pp. 513-523
[328.]
D.S. Robinson, D.A. Campbell, S.R. Durham, J. Pfeffer, P.J. Barnes, K.F. Chung, Asthma and Allergy Research Group of the National Heart and Lung Institute.
Systematic assessment of difficult-to-treat asthma.
Eur Respir J, 22 (2003), pp. 478-483
[329.]
N.W. Wainwright, P.G. Surtees, N.J. Wareham, B.D. Harrison.
Psychosocial factors and incident asthma hospital admissions in the EPIC-Norfolk cohort study.
Allergy, 62 (2007), pp. 554-560
[330.]
M.A. Berry, B. Hargadon, M. Shelley, D. Parker, D.E. Shaw, R.H. Green, et al.
Evidence of a role of tumor necrosis factor alpha in refractory asthma.
N Engl J Med, 354 (2006), pp. 697-708
[331.]
J.B. Morjaria, A.J. Chauhan, K.S. Babu, R. Polosa, D.E. Davies, S.T. Holgate.
The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial.
Thorax, 63 (2008), pp. 584-591
[332.]
S. Wenzel.
Severe asthma in adults.
Am J Respir Crit Care Med, 172 (2005), pp. 149-160
[333.]
C. Miranda, A. Busacker, S. Balzar, J. Trudeau, S.E. Wenzel.
Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation.
J Allergy Clin Immunol, 113 (2004), pp. 101-108
[334.]
J. Bousquet, P. Cabrera, N. Berkman, R. Buhl, S. Holgate, S. Wenzel, et al.
The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma.
Allergy, 60 (2005), pp. 302-308
[335.]
I.L. Bernstein, D.I. Bernstein, M. Chan-Yeung, J.L. Malo.
Definitions and classification of asthma in the workplace.
Asthma in the worplace, 3.ª ed., pp. 1-8
[337.]
M. Kogevinas, J.P. Zock, D. Jarvis, H. Kromhout, L. Lillienberg, E. Plana, et al.
Exposure to substances in the workplace and new-onset asthma: an international prospective populationbased study (ECRHS-II).
Lancet, 28 (2007), pp. 336-341
[338.]
J.L. Malo.
Prevention of occupational asthma.
Proceedings of the first Jack Pepys occupational asthma symposium, 167 (2003), pp. 463-464
[339.]
H. Jeal, A. Draper, M. Jones, J. Harris, K. Welsh, A.N. Taylor, et al.
HLA associations with occupational sensitization to rat lipocalin allergens: a model for other animal allergies?.
J Allergy Clin Immunol, 111 (2003), pp. 795-799
[340.]
J.L. Malo, C. Lemiere, A. Desjardins, A. Cartier.
Prevalence and intensity of rhinoconjuntivitis in subjects with occupational asthma.
Eur Respir J, 10 (1997), pp. 1513-1515
[341.]
A. Karjalainen, R. Mortikainen, T. Khukka, K. Saarinen, T. Uitt.
Risk of asthma among Finnish patients with occupational rhinitis.
Chest, 123 (2003), pp. 283-288
[342.]
A. Pronk, L. Preller, M. Raulf-Heimsoth, I.C. Jonkers, J.W. Lammers, I.M. Wouters, et al.
Respiratory symptoms,sensitization, and exposure response relationships in spray painters exposed to isocyanates.
Am J Respir Crit Care Med, 176 (2007), pp. 1090-1097
[343.]
M. Chan-Yeung, J.L. Malo.
Occupational asthma.
N Engl J Med, 333 (1995), pp. 107-112
[344.]
O. Vandenplas, A. Cartier, J.L. Malo.
Occupational challenge test.
Asthma in the workplace, 3.ª ed., pp. 227-252
[345.]
G. Rachiotis, R. Savani, A. Brant, S.J. MacNeill, A. Newman-Taylor, P. Cullinan.
The outcome of occupational asthma after cessation of exposure: a systematic review.
Thorax, 62 (2007), pp. 147-152
[346.]
M. Padoan, V. Pozzato, M. Simoni, L. Zedda, G. Milan, L. Bononi, et al.
Longterm follow-up of toluene diisocyanateinduced asthma.
Eur Respir J, 21 (2003), pp. 637-640
[347.]
P. Cullinan, S. Tarlo, B. Nemery.
The prevention of occupational asthma.
Eur Respir J, 22 (2003), pp. 853-860
[348.]
S.M. Brooks, M.R. Weiss, I.L. Bernstein.
Reactive airways dysfunction syndrome (RADS): persistent asthma syndrome after high level irritant exposures.
Chest, 88 (1985), pp. 376-384
[349.]
S.M. Tarlo, L.P. Boulet, A. Cartier, D. Cockcroft, J. Coté, F.E. Hargreave, et al.
Canadian Thoracic Society guidelines for occupational asthma.
Can Respir J, 5 (1998), pp. 289-300
[350.]
S.M. Brooks, Y. Hammad, I. Richards, J. Giovinco-Barbas, K. Jenkins.
The spectrum of irritant-induced asthma. Sudden and not-so-sudden onset and the role of allergy.
Chest, 113 (1998), pp. 42-49
[351.]
S.M. Tarlo, J. Balmes, R. Balkissoon, J. Beach, W. Beckett, D. Bernstein, et al.
Diagnosis and management of workrelated asthma: American College Of Chest Physicians Consensus Statement.
Chest, 134 (2008), pp. 1S-41S
[352.]
P.K. Henneberger.
Workexacerbated asthma.
Curr Opin Allergy Clin Immunol, 7 (2007), pp. 146-151
[353.]
K.L. Christopher, R.P. Wood, R.C. Eckert, F.B. Blager, R.A. Raney, J.F. Souhrada.
Vocalcord dysfunction presenting as asthma.
N Engl J Med., 308 (1983), pp. 1566-1570
[354.]
R.P. Wood, H. Milgrom.
Vocal cord dysfunction.
J Allergy Clin Immunol, 98 (1996), pp. 481-485
[355.]
S. Kayani, D.C. Shannon.
Vocal cord dysfunction associated with exercise in adolescent girls.
Chest, 113 (1998), pp. 540-542
[356.]
E.R. McFadden, D.K. Zawadski.
Vocal cord dysfunction masquerading as exerciseinduced asthma. a physiologic cause for “choking” during athletic activities.
Am J Respir Crit Care Med, 153 (1996), pp. 942-947
[357.]
K.B. Newman, U.G. Mason, K.B. Schmaling.
Clinical features of vocal card dysfunction.
Am J Respir Crit Care Med, 152 (1995), pp. 1382-1386
[358.]
D.R. Doshi, M.M. Weinberger.
Longterm outcome of vocal cord dysfunction.
Ann Allergy Asthma Immunol, 96 (2006), pp. 794-799
Copyright © 2009. Sociedad Española de Neumología y Cirugía Torácica
